By Tom Winnifrith, The Sheriff of AIM | Wednesday 26 October 2016
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Earlier today I pointed out how Lord David Evans, the senior NED at Advanced Oncotherapy (AVO) sold his entire holding of shares during a closed period and just ahead of a major placing. He appears only to have told the company this week, although the share sales took place between 19 August 2016 and 16 September 2016. This is a massive breach of AIM Rule 21. I have written to Marcus Stuttard, the head of the Oxymorons at AIM Regulation.
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen